Balaxi Pharmaceuticals Share Price
Start SIP in Balaxi Pharmaceuticals
Start SIPBalaxi Pharmaceuticals Performance
Day Range
- Low 111
- High 115
52 Week Range
- Low 80
- High 151
- Open Price111
- Previous Close110
- Volume91890
Balaxi Pharmaceuticals Investment Rating
-
Master Rating:
-
Balaxi Pharmaceuticals has an operating revenue of Rs. 240.96 Cr. on a trailing 12-month basis. An annual revenue de-growth of -30% needs improvement, Pre-tax margin of 1% needs improvement, ROE of -1% is poor and needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around -0% and 4% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 32 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 19 | 16 | 13 | 17 | 25 | 30 |
| Operating Expenses Qtr Cr | 18 | 16 | 12 | 16 | 21 | 25 |
| Operating Profit Qtr Cr | 2 | 0 | 0 | 1 | 4 | 5 |
| Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Qtr Cr | 0 | 1 | 0 | 0 | 0 | 0 |
| Tax Qtr Cr | 1 | 0 | 0 | 0 | 1 | 1 |
| Net Profit Qtr Cr | 1 | -1 | 0 | 1 | 3 | 4 |
Balaxi Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 14
- Bearish Moving Average
- ___
- 2
- 20 Day
- ₹110.02
- 50 Day
- ₹111.51
- 100 Day
- ₹112.20
- 200 Day
- ₹109.63
- 20 Day
- ₹109.06
- 50 Day
- ₹110.85
- 100 Day
- ₹116.59
- 200 Day
- ₹108.10
Balaxi Pharmaceuticals Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 115.39 |
| Second Resistance | 116.84 |
| Third Resistance | 119.04 |
| RSI | 57.54 |
| MFI | 84.90 |
| MACD Single Line | -0.64 |
| MACD | 0.08 |
| Support | |
|---|---|
| First Support | 111.74 |
| Second Support | 109.54 |
| Third Supoort | 108.09 |
Balaxi Pharmaceuticals Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 91,890 | 5,344,322 | 58.16 |
| Week | 239,626 | 10,675,320 | 44.55 |
| 1 Month | 110,506 | 4,279,897 | 38.73 |
| 6 Month | 46,087 | 2,167,000 | 47.02 |
Balaxi Pharmaceuticals Result Highlights
Balaxi Pharmaceuticals Synopsis
NSE-Medical-Generic Drugs
Balaxi Pharmaceutica is involved in the business activities of Wholesale of household goods. Company’s Total Operating Revenue is Rs. 70.20 Cr. and Equity Capital is Rs. 10.90 Cr. for the Year ended 31/03/2024. Balaxi Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/09/1942 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L25191TG1942PLC121598 and registration number is 000045.| Market Cap | 629 |
| Sales | 64 |
| Shares in Float | 1.88 |
| No of funds | 3 |
| Yield |
| Book Value | 5.11 |
| U/D Vol ratio | 0.9 |
| LTDebt / Equity | |
| Alpha | 0.08 |
| Beta | 0.55 |
Balaxi Pharmaceuticals Shareholding Pattern
| Owner Name | Jun-24 | Mar-24 |
|---|---|---|
| Promoters | 65.99% | 66.86% |
| Foreign Portfolio Investors | 16.88% | 17.21% |
| Financial Institutions/ Banks | 0.02% | 0.02% |
| Individual Investors | 8.6% | 7.43% |
| Others | 8.51% | 8.48% |
Balaxi Pharmaceuticals Management
| Name | Designation |
|---|---|
| Mr. Ashish Maheshwari | Managing Director |
| Mrs. Minoshi Maheshwari | Non Executive Director |
| Mrs. Purnima Singh Kamble | Independent Director |
| Mr. Mangina Srinivas Rao | Independent Director |
| Mr. Gandhi Gamji | Independent Director |
| Mr. Kunal Mahendra Bhakta | Independent Director |
Balaxi Pharmaceuticals Forecast
Price Estimates
Balaxi Pharmaceuticals Corporate Action
Balaxi Pharmaceuticals FAQs
What is Share Price of Balaxi Pharmaceuticals ?
Balaxi Pharmaceuticals share price is ₹113 As on 18 September, 2024 | 02:31
What is the Market Cap of Balaxi Pharmaceuticals ?
The Market Cap of Balaxi Pharmaceuticals is ₹629 Cr As on 18 September, 2024 | 02:31
What is the P/E ratio of Balaxi Pharmaceuticals ?
The P/E ratio of Balaxi Pharmaceuticals is 13.8 As on 18 September, 2024 | 02:31
What is the PB ratio of Balaxi Pharmaceuticals ?
The PB ratio of Balaxi Pharmaceuticals is 3.1 As on 18 September, 2024 | 02:31